Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PRTK

Paratek Pharmaceuticals (PRTK) Stock Price, News & Analysis

Paratek Pharmaceuticals logo

About Paratek Pharmaceuticals Stock (NASDAQ:PRTK)

Advanced Chart

Key Stats

Today's Range
$2.23
$2.23
50-Day Range
$2.17
$2.23
52-Week Range
$1.29
$3.65
Volume
N/A
Average Volume
724,253 shs
Market Capitalization
$127.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PRTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PRTK Stock News Headlines

The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.tc pixel
Paratek Pharmaceuticals to acquire Optinose in $330M transaction
See More Headlines

PRTK Stock Analysis - Frequently Asked Questions

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) announced its quarterly earnings results on Monday, November, 8th. The specialty pharmaceutical company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.08. The specialty pharmaceutical company earned $24.45 million during the quarter, compared to the consensus estimate of $22.98 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Paratek Pharmaceuticals investors own include Energy Transfer (ET), Sorrento Therapeutics (SRNE), Micron Technology (MU), Verastem (VSTM), Citius Pharmaceuticals (CTXR), SCYNEXIS (SCYX) and Aurinia Pharmaceuticals (AUPH).

Company Calendar

Last Earnings
11/08/2021
Today
8/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:PRTK
Previous Symbol
NASDAQ:TSPT
CIK
1178711
Employees
268
Year Founded
1996

Profitability

EPS (Trailing Twelve Months)
($1.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$63.57 million
Net Margins
-35.44%
Pretax Margin
-35.35%
Return on Equity
N/A
Return on Assets
-40.05%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.52
Quick Ratio
0.46

Sales & Book Value

Annual Sales
$160.27 million
Price / Sales
0.80
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($3.08) per share
Price / Book
-0.72

Miscellaneous

Outstanding Shares
57,320,000
Free Float
52,736,000
Market Cap
$127.82 million
Optionable
Optionable
Beta
1.70

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:PRTK) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners